Histochemical approaches to assess cell-to-cell transmission of misfolded proteins in neurodegenerative diseases

G. Natale,1 E. Pompili,2 F. Biagioni,1 S. Paparelli,1 P. Lenzi,1 F. Fornai1,3
1Department of Human Morphology and Applied Biology, University of Pisa;
2Department of Morphological Sciences, University La Sapienza, Rome;
3I.R.C.C.S., Neuromed, Pozzilli (IS), Italy

Abstract

Formation, aggregation and transmission of abnormal proteins are common features in neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. The mechanisms underlying protein alterations in neurodegenerative diseases remain controversial. Novel findings highlighted altered protein clearing systems as common biochemical pathways which generate protein misfolding, which in turn causes protein aggregation and protein spreading. In fact, proteinaceous aggregates are prone to cell-to-cell propagation. This is reminiscent of what happens in prion disorders, where the prion protein misfolds thus forming aggregates which spread to neighbouring cells. For this reason, the term prionoids is currently used to emphasize how several misfolded proteins are transmitted in neurodegenerative diseases following this prion-like pattern. Histochemical techniques including the use of specific antibodies covering both light and electron microscopy offer a powerful tool to describe these phenomena and investigate specific molecular steps. These include: prion-like protein alterations; glycation of prion-like altered proteins to form advanced glycation end-products (AGEs); mechanisms of extracellular secretion; interaction of AGEs with specific receptors placed on neighbouring cells (RAGEs). The present manuscript comments on these phenomena aimed to provide a consistent scenario of the available histochemical approaches to dissect each specific step.

Introduction

The occurrence of protein aggregates

Neurodegenerative diseases (NDs) are chronic and progressive conditions which may affect, separately or in combination, autonomic, motor, sensory, mood and cognitive functions. Apart from juvenile cases, most of which are genetically determined, these disorders appear late in life, being characterized by marked neuronal loss which was traditionally described as trans-synaptic degeneration.1 At present, therapeutic strategies aimed at treating or preventing these disorders are under intense investigation.

Despite the occurrence of multiple mechanisms to generate cell pathology, the common feature which represents the starting point of disease progression is the occurrence of misfolded proteins. This point is key also for current histochemistry which allows detecting early in the disease process the occurrence of cell pathology. In fact, various NDs share the presence of altered protein aggregates within neuronal and non-neuronal cells. These proteins are expected to misfold, aggregate and propagate to sustain disease progression. For such a reason, these NDs are defined as protein misfolding diseases (PMDs) or conformational disorders. For instance, due to pathological conditions, normal proteins domain owing an α-helix may misfold into β-sheet structures whose conformation is further stabilized by pathobiochemical interactions, leading to the formation of oligomers that cannot be cleared.2-5

Misfolded proteins are pathological hallmarks which may be in common with different disorders or vary in specific diseases. For instance, α-synuclein aggregates characterize Parkinson’s disease (PD)6 and other synucleinopathies,7 whereas TDP43 and SOD1 are typically found as protein aggregates in amyotrophic lateral sclerosis (ALS).8 Huntington aggregates characterize Huntington’s disease,10 whereas β-amyloid and tau are typical of degenerative dementia.11 In some cases, the same protein misfolds and accumulates in multiple disorders, such as TDP-43 and SOD1, which can be found both in ALS and fronto-temporal dementia.12 This concomitance indicates a continuum of disease progression13 and occurs more often for α-synuclein which may be found in a wide range of disorders. In fact, α-synuclein accumulates in Parkinsonism (including multiple system atrophy) but also in ALS12 in Huntington’s disease14 and in specific forms of degenerative dementia.15 This poses the α-synuclein detection as a powerful marker to track neurodegeneration. In fact, the mechanisms by which α-synuclein misfolds, aggregates, propagates and leads to cell death are intensely investigated.14 The presence of altered α-synuclein in a variety of disorders is unlikely to be a coincidence but it rather witnesses for progressive involvement of different neuronal networks along the course of neurodegeneration.11,12,15

Histochemical detection of misfolded protein aggregates through the use of specific and sensitive antibodies allowed, in the last decades, enormous progress in the diagnosis and nosography of NDs. In particular, both light and electron microscopy, by profiting of sophisticated technologies to produce and characterize antibodies, provided a fairly disease-specific pattern of cell pathology. In this way, even in the presence of neuronal accumulation of α-synuclein, it is possible to distinguish whether this aggregation follows a Lewy body (LB)-like pattern (such as in Parkinsonism, where inclusions are formed by a negative α-synuclein core which is surrounded by α-synuclein-containing radiating filaments) or it is characterized by α-synuclein-positive neuronal vacuoles (as it occurs in Huntington’s disease).16 The co-expression of α-synuclein with other protein aggregates is typical in specific diseases. This is the case of co-accumulation of α-synuclein with SOD1 in ALS,13 co-accumulation of α-synuclein with huntingtin in Huntington’s disease17 or co-expression of α-synuclein, parkin and ubiquitin in PD.18 The cell type in α-synuclein aggregates is also useful in differential diagnosis. For instance, α-synuclein accumulates within neuronal cells in PD but also involves glial cells in multiple system atrophy.19

Protein aggregates are based upon protein misfolding

Why a given protein aggregates within neurons may depend on several mechanisms which in turn fall in two main classes: i) altered protein synthesis; ii) altered protein metabolism. In the first case, the gene coding for a certain protein is present in excess20 or it is altered by point mutations.21 In these cases, the nascent protein is

Correspondence: Dr. Francesco Fornai, Department of Human Morphology and Applied Biology, University of Pisa, via Roma 55, 56126 Pisa, Italy. Tel. +39.050.2218601 - Fax: +39.050.2218606. E-mail: francesco.fornai@med.unipi.it

Key words: advanced glycation end-products, exosome, synucleinopathies, neurodegenerative diseases, prion diseases, prionoids, RAGES.

Contributions: G.N. and E.P. equally contributed to the manuscript.

Received for publication: 27 July 2012.
Accepted for publication: 7 September 2012.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright G. Natale et al., 2013 Licensee PAGEPress, Italy European Journal of Histochemistry 2013; 57:e5 doi:10.4081/ejh.2013.e5

[European Journal of Histochemistry 2013; 57:e5] [page 31]
proteins. This is the case of increased protein level (detected by SDS-PAGE immunoblotting). Again, if the gene is mutated, this can be detected by genetic analysis or the use of mutation specific antibodies. The occurrence of altered protein metabolism relies on two main protein clearing systems which are effective in eukaryotic cells, namely the ubiquitin-proteasome system (UPS) and the autophagy pathway. There are now refined guidelines to detect the efficacy of these pathways and to establish the specific step which is impaired thus affecting protein metabolism. When a deficiency in either UPS or autophagy occurs, the excess of protein substrates leads to protein misfolding and aggregation. Immunochemistry now provides the chance to cellular prion protein (PrPc) and PrPsc. Pre-treatment with the sample with proteinase-K (PK) which destroys soluble proteins but cannot interact with misfolded protein aggregates, leaving intact their epitopes. This allows identifying authentic misfolded variants of prionoids. Therefore, the use of PK treatment, prior to immunohistochemistry, is routinely applied to remove folded proteins and detect their misfolded isoforms. The paradigm is represented by the immunoreactivity against cellular prion protein (PrPc) and PrPsc. Pre-treatment with PK is also used to detect unsoluble α-synuclein modified as β-sheet oligomers as it occurs in dopamine (DA)-related neurodegenerative conditions or following the upregulation of α-synuclein DA adducts. Apart from PK, which acts as a protease, the disruption of the secondary structure can also be carried out with the denaturing agent sodalysin sarkosyl according to Takahashi et al. Sarkosyl is sodium lauroyl sarcosinate, which reacts as an anionic detergent. This allows disrupting the strong binding within proteins which are critical to maintain the secondary structure.

From an exquisite methodological perspective, it is worth mentioning potential discrepancies between pre-treatment with sarkosyl compared with PK. This is likely to depend on the loss of specific epitopes of the primary structure following the stronger effects of PK, whereas sarkosyl is expected to preserve entirely the amino acid chain of misfolded proteins. Therefore, it is not surprising that in some instances PK treatment leads to a total loss of staining, even in the presence of misfolded prionoids, whereas sarkosyl provides a fair antigen preservation. On the other hand, sarkosyl may lead to less specific results.

What happens to misfolded proteins

The status of misfolded protein in the form of AGEs confers to the prionoids the ability to spread from cell to cell. In fact AGEs can be expressed at the level of the plasma membrane from where they are released extracellularly. The combined histochemistry to detect glycated protein with the use of prionoid-specific antibodies allows detecting AGE on the plasma membranes. At the same time, AGEs contained in the endosomal compartment can merge with the plasma membrane and being released as exosomes in the extracellular space. The presence of specific receptor for AGEs, termed RAGEs, allows binding and entering prionoids at the level of neighbouring cells. Thus, misfolded proteins can either aggregate and persist in the original cell or move out to spread the disease. In the first case, protein aggregation may seed the formation of neuronal inclusions such as LB in PD. These inclusions should not be regarded as static milestones. In fact, their detection by light and electron microscopy allows pathological diagnosis, they also represent dynamic structures which preserve antigen properties and enzymatic activity. In keeping with this, it is worth mentioning that protein clearing systems, such as UPS and autophagy, still persist within neuronal inclusions and own catalytic activity. By using advanced techniques of immuno-electron microscopy it is possible to purify misfolded protein aggregates (such as α-synuclein-containing aggregates) from neurons and assess the presence of specific enzyme belonging to the UPS or autophagy. This method is based on magnetic beads which bind to streptavidin and allow isolating α-synuclein containing structures. Lenzi et al. provided the description of this technique applied to the field of neurodegeneration. This procedure allows purifying in a prionoid-specific manner neuronal aggregates. An alternative technique based on differential
centrifugation of neuronal pools allows localizing misfolded protein aggregates within specific cell compartments (including pathological compartments such as neuronal inclusions) where prionoids co-localize with protein clearing enzymes (see electron micrographs in Figure 1 for both procedures). The occurrence of enzymatic activity within misfolded prionoid aggregates suggests that these structures may represent the remnant of a compensatory mechanism which still engages misfolded substrates for their metabolism. In fact, it is a matter of debate whether prionoids aggregates are neuroprotective or rather their misfolded constituents exert neurotoxicity when available for various cell structures.

In spite of the faith of prionoid-containing neuronal inclusions for the original neuron, it is fascinating that in recent years these misfolded proteins were shown to spread from cell to cell. Prionoids spreading is supposed to occur via different mechanisms each including various steps described in the following paragraph.

### How misfolded proteins spread from cell to cell

Recent evidence shows that self-propagation of the protein misfolding process is similar to prion diseases. In keeping with AGEs, their interaction with specific RAGEs represents a critical step. In fact, AGEs derived from specific prionoids including β-amyloid, tau, α-synuclein are implicated in cell-to-cell transmission. Namely, AGEs can interact with specific receptors, named RAGEs, placed on brain endothelium, microglia and neurons. The investigation of AGEs-RAGEs interaction opens new insights in the knowledge of cell-to-cell transmission of altered proteins or the implication of glia in the propagation of these altered proteins.

At present, immunohistochemistry provided the chance to label and localize RAGEs in combination with major histocompatibility proteins bridging the spreading of neurodegeneration with altered immune system. This is further substantiated by the primary structure of RAGEs which belong to the superfamily of immunoglobulins. In fact, RAGEs possess three immunoglobulin domains, one extracellular V (variable) type and two C (constant) types which anchor the receptor to the cell membrane. The V domain binds AGEs and β-sheet chains. The binding of AGEs with RAGEs, apart from spreading prionoids, triggers a variety of transduction mechanisms which activate various biochemical cascade in neighbouring cells. These include RAGE-mediated activation of Protein Kinase C and NF-κB which leads to a further increase in RAGE expression by a positive feedback mechanism. Such a vicious circle may magnify the deleterious effects of prionoids spreading extracellularly. Apart from RAGEs, other mechanisms, including exosomes, tunnelling nanotubes, and trogocytosis, seem to be responsible for such a transmission.

Protein aggregates are often associated with the membrane trafficking machinery. This topography is critical for the fact of altered protein aggregates. In the case of prion disease, an endocytic recycling pathway has been demonstrated. Double immunostaining, with fluorescent probes (i.e., fluorescein and rodamine), allows detecting aggregates co-localised with different cell organelles, such as exosomes and microtubules. This immunohistochemical analysis demonstrated the association between exosomes and protein aggregates. Morphological investigations of exosomes are critical considering that exosomes have been shown to secrete in the extracellular space prions, β-amyloid peptides, and α-synuclein.

Cell-to-cell spreading of prionoids represents a hot research topic which is investigated in its specific steps. This process appears to be critical for the progression of neurodegenerative disorders and configures as a solid bridge between altered protein clearance, protein aggregates, post-translational protein alterations, and cell to cell transmission. This
latter point applies both to altered neuronal transmission and altered immune networks which at this level possess a remarkable overlapping and enhance each other.

The chance to detect these specific steps by dedicated histochemical approaches was emphasized in the light of future research efforts.

References

1. Lach B, Grimes D, Benoit B, Minkiewicz-Janda A. Caudate nucleus pathology in Parkinson’s disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol 1992;83:350-60.

2. Conway KA, Rochet JC, Bieganowski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294: 1346-9.

3. Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol 2008;65: 184-9.

4. Natale G, Pasquali L, Paparelli A, Foraini F. Parallel manifestations of neuropathologies in the enteric and central nervous systems. Neurogastroenterol Motil 2011; 23: 1056-63.

5. Natale G, Ferrucci M, Lazzeri G, Paparelli A, Foraini F. Transmission of prions within the gut and towards the central nervous system. Prion 2011; 5: 142-9.

6. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.

7. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186-90.

8. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003;18: S2-12.

9. Rusina R, Kovacs GG, Fiala J, Porubcová J, Horka J, Ridzo ER. S2-12. Alpha-synuclein immunoreactivity of synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186-90.

10. Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH, et al. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s disease patients and transgenic mouse models. Neurosc Lett 2000;289:29-32.

11. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532-40.

12. Polyemenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011;147:498-508.

13. Martin LJ. Transgenic mice with human mutant genes causing Parkinson’s disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev Neurosci 2007;18:115-36.

14. Steiner JA, Angot E, Brundin P. A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ 2011;18: 1425-33.

15. Gilbert RM, Fahn M, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord 2010;25: 1868-85.

16. Vivaqua G, Casini A, Vaccaro R, Salvi EP, Pasquali L, Foraini F, et al. Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies. J Chem Neuroanat 2011;42:327-40.

17. Vivaqua G, Biagiioni F, Yu S, Casini A, Bucci D, D’Este L, et al. Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice. J Chem Neuroanat 2012;44:76-85.

18. Corrochano S, Renna M, Tomas-Zapico C, Brown SD, Lucas JH, Rubinsztein DC, et al. α-Synuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology. Autophagy 2012; 8: 341-32.

19. Shults CW. Lewy bodies. Proc Natl Acad Sci USA 2006;103:1661-8.

20. Campbell BC, McLean CA, Culvenor JG, Brown SD, Lucas JH, Rubinsztein DC, et al. α-Synuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology. Autophagy 2012; 8: 341-32.

21. Zarranz JJ, Alegre J, Gómez-Esteban JC, Castello S, Jiménez C, et al. Migration of synuclein-containing synuclein-positive Lewy bodies via autophagy. Autophagy 2009;5:585-9.

22. Emmanouilidou E, Melachroinou K, Karagiannidis A, Caudate nucleus pathology in Parkinson's disease: the effects of protein glycation. J Pathol 2010;222:13-25.

23. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloid, prions, and prionoids. Neuron 2009;64:783-90.

24. Grillo MA, Colombo S. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids. 2008;35:29-36.

25. Lit J, Liu D, Sun L, Lu V, Zhang Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspectives. J Neurosci Res. 2012; 317:1-5.

26. Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Saierdo J, Miallah E, et al. Behavioral and biptopathological consequences of parquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 2007;61:991-1001.

27. Haritani M, Spencer YL, Wells GA. Hydrated autolcave pretreatment enhancement of prion protein immunoreactivity in forma-lin-fixed bovine spongiform encephalopa-thy-affected brain. Acta Neuropathol 1994; 87:86-90.

28. Rosicarelli B, Serafini B, Shriccoli M, Lu M, Cardone F, Pochiari M, et al. Migration of dendritic cells into the brain in a mouse model of prion disease. J Neuroimmunol 2005;165:114-20.

29. Takahashi RH, Tobiume M, Sato Y, Sata T, Gours GK, Takahashi H. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer’s disease brain. Neuropathology 2011;31:208-14.

30. Rahman S, Arair S, Sajio S, Yamato I, Murata T. Sarkosyl is a good regeneration reagent for studies on vacuolar-type ATPase subunit interactions in Biancore experiments. Anal Biochem 2011;418:301-3.
Roumelliotis, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci 2010;30:6838-51.

40. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, di Poggio G, Mauceli G, Busceti CI, Pellegrini A, Bodner RA, Outeiro TF, Altmann S, Lenzi P, Fulceri F, Lazzeri G, Casini A, Fornai F, Lenzi P, Gesi M, Ferrucci M, Ekström P, Mattsson B, Björklund A, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington’s and Parkinson’s diseases. Proc Natl Acad Sci USA 2006;103:11172-77.

41. Koch M, Chitayat S, Dattilo BM, Schiefer A, Diez J, Chazin WJ, et al. Structural basis for ligand recognition and activation of RAGE. Structure 2010;18:1342-32.

42. Chen L, Wei Y, Wang X, He R. Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 2010;5:e9652.

43. Lue LF, Walker DG, Brachova L, Yan SD. Involvement of microglial receptor for advanced glycation endproducts (rAGE) in alzheimer’s disease: identification of a cellular activation mechanism Exp Neurol 2001;172:29-45.

44. Sasaki N, Toki S, Chowe H, Saito T, Nakano N, Hayashi Y, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease Brain Res 2001;888: 256-262.

45. Zlokovic B.V. New therapeutic targets in the neurovascular pathway in Alzheimer’s disease Neurotherapeutics 2008;5:409-414.

46. Ma li ska D, Laure-Ramionowska M, Taraszewska A, Der gowski K, Ma li ski S. Immunodistribution of amyloid beta protein (Aβ) and advanced glycation end-product receptors (RAGE) in choroid plexus and ependyma of resuscitated patients. Folia Neuropathol 2011;49:295-300.

47. Askarova S, Yang X, Sheng W, Sun GY, Lee JC. Role of Aβ-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A2 activation in astrocytes and cerebral endothelial cells. Neuroscience 2011;199:375-85.

48. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;106:759-95.

49. Casula M, Iyer AM, Spliet WG, Anink JJ, Steentjes K, Sta M, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011;179:233-43.

50. Neper M, Schmidt AM, Brett J, Yan SD, Fang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004.

51. Chivet M, Hemming F, Pernet-Gallay K, Fraboulet S, Sadoul R. Emerging role of neuronal exosomes in the central nervous system. Front Physiol 2012;3:145.

52. Gousset K, Zurzolo C. Tunnelling nanotubes: a highway for prion spreading? Prion 2009;3:94-8.

53. Ahmed KA, Xiang J. Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med 2011;15: 1458-73.

54. Yamasaki T, Suzuki A, Shimizu T, Watarai M, Hasebe R, Horiuchi M. Characterization of intracellular localization of prP(Sc) in prion-infected cells using a mAb that recognizes the region consisting of aa 119-127 of mouse PrP. J Gen Virol 2012;93:668-80.

55. Santa-Maria I, Varghese M, Ksiezk-Reding H, Dzhun A, Wang J, Pasinetti GM. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of tau protein in aggresomes. J Biol Chem 2012;287:20522-33.

56. Vella LJ, Sharples RA, Nisbet RM, Cappai R, Hill AF. The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J 2008;37:323-32.

57. Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, et al. Cells release prions in association with exosomes. Proc Natl Acad Sci USA 2004;101:9683-8.

58. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, et al. Alzheimer’s disease amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA 2006;103:11172-77.